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Nowak’s model of the human immunodeﬁciency virus (HIV) infection has been extensively and successfully used to simulate the
interaction between HIV and cytotoxic lymphocyte- (CTL-) mediated immune response. However, this model is not available for
hepatitis B virus (HBV) infection. As the enhanced recruitment of virus-speciﬁc CTLs into the liver has been an important novel
concept in the pathogenesis of hepatitis B, we develop a speciﬁc mathematical model analyzing the relationship between HBV
and the CTL-mediated immune response, and the indicator of the liver cell damage, alanine aminotransferase (ALT). The stability
condition of the complete recovery equilibrium point at which HBV will be eliminated entirely from the body is discussed. A
diﬀerent set of parameters is used in the simulation, and the results show that the model can interpret the wide variety of clinical
manifestations of HBV infection. The model suggests that a rapid and vigorous CTL response is required for resolution of HBV
infection.
Copyright © 2008 Changjiang Long et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Infection with the hepatitis B virus (HBV) is a major health
problem, which can lead to cirrhosis and primary hepatocel-
lular carcinoma (HCC). More than 2 billion people alive to-
day have been infected by HBV. The population of HBV car-
rier is about 400 million, of whom 75% are located in Asia.
Accordingly, HBV causes approximately 1 million deaths
each year worldwide. In China alone, nearly 15 million new
infections occur annually, more than 30 million people are
chronically infected, and more than 350 thousand of them
die each year from cirrhosis and HCC.
In order to ﬁnd an eﬃc i e n tw a yt op r e v e n ta n dt r e a tt h e
infection, it is of great importance to understand the im-
munopathogenesis of HBV. Although molecular techniques
have provided fundamental insight into the ﬁne detail of the
interaction between HBV and immune system, many biolog-
ically important questions are not primarily concerned with
the molecular mechanisms of immune recognition but with
the population dynamics of the immune response. Mathe-
matical models are always needed to answer these questions.
Studies on humans infected with HIV-1 and macaques in-
fected with simian immunodeﬁciency virus (SIV) show that
cytotoxiclymphocytes(CTLs)arecriticalincontrollingvirus
replication [1]. Virus mutants of human immunodeﬁciency
virus(HIV)andSIVareabletoescapethedominant CTLre-
sponse and become the major replicating strains in vivo [1].
In contrast to HIV and many other viruses, cell culture sys-
tems that allow eﬃcient in vitro infection and passaging of
virus are not available for HBV, which is hepatotropic and
noncytopathic. Recent studies on HBV pathogenesis in ani-
mal models demonstrated that the enhanced recruitment of
virus-speciﬁcCTLsintothelivercellsiscriticalforthepatho-
genesis of both HBV infection and hepatocellular carcinoma
[2, 3]. The most common mathematical model in HIV in-
fection is presented by Nowak to explain the dynamics of
CTL-mediatedhostimmuneresponsetoHIVandthepatho-
genesis of AIDS [4]. Mathematical models, which are not
based on CTL-mediated host response, have been proposed
for modeling HBV or HCV infection and evaluating the ef-
fectiveness of antiviral therapy [5–8]. Even the models de-
scribing the interactions between host immune response and2 Journal of Biomedicine and Biotechnology
virus were built to explain the mechanism of acute hepati-
tis [9–11]. However, these models fail to explain the various
outcomes of HBV infection [12].A newmathematicalmodel
for dissecting the role of CTL in HBV diseases is needed for
the following reasons.
(1) Being diﬀerent kinds of viruses, HIV is cytopathic
virus and HBV is a noncytopathic virus [12], that is,
cells infected by HBV will not be killed by virus di-
rectly, cellular function and lifespan of HBV-infected
hepatocytes are almost the same as that of the unin-
fected cells in vitro [13]. The death rate of noncyto-
pathic virus-infected cells in the absence of immunity
equals that of uninfected target cells [14]. The lifespan
of HBV-infected cells varies greatly in vivo which is
mainly due to the strength of the anti-HBV CTL re-
sponse [15]. CTL will not only kill but also cure the
infected hepatocytes by a nonlytic eﬀector mechanism
[16, 17]. The eﬀect of CTL response should be consid-
ered in the model.
(2) The non-CTL models ignore the kinetics of hepato-
cytereplication.Actually,bothuninfectedandinfected
hepatocytes can replicate at the same rate [13]. In-
fected cells are generated not only from normal cells
infected by HBV, but also from replication of its own
[18, 19].
(3) In the non-CTL models, the equilibrium abundance
of infected cells depends only on the immunological
parameters [6]; but in fact the characteristic of HBV
also has great inﬂuence on the result [12].
(4) The value of alanine aminotransferase (ALT) in the
blood stream is generally taken to be an indicator of
the liver cell damage [9]. ALT was not included in the
non-CTL models.
2. MATERIALS AND METHODS
2.1. Mathematicalmodels
The model contains six variables, that is, uninfected hepa-
tocytes (X), infected hepatocytes (Y), total host hepatocytes
(N = X + Y), free virus (V), a CTL response (Z), and ALT.
The changes of population over time can be described by a
system of diﬀerential equations.
The corresponding mathematics equations are
dX
dt
= F(N)X −d1X −b1XV +k1YZ,
dY
dt
= F(N)Y +b1XV −d1Y −
 
k1 +k2
 
YZ,
dV
dt
= k3Y −d3V,
dZ
dt
=
 
g4 +k4YZ
  
1 −
Z
Zmax
 
− d4Z,
dALT
dt
= k5
 
d1X +d1Y +k2YZ
 
− d5ALT,
F(N) =
d1
N3, N = X +Y,
X0 = 1, Y0 = 0, V0 = 0, Z0 =
g4
d4
,
ALT0 = k5
d1
d5
d
1
, N0 = 1,
(1)
where F(N)i st h en a t u r a lg r o w t hr a t eo fh e p a t o c y t e s .I ti s
a monotonically decreasing function [20]. We took F(N) =
d1/N3 [13]; F(N) = d1 when N = 1 (without loss of gen-
erality, we take the cell and virus concentrations to be scaled
suchthatintheuninfectedsystemthetotalcellconcentration
is N = 1[ 18, 19]).
Both uninfected and infected hepatocytes replicate at a
rate F(N) and die at a rate d1, while uninfected ones are in-
fectedbyvirusatarateb1XV.TheCTLresponsecanactivate
two diﬀerent pathways to eliminate a virus, either by killing
the infected cells or by eliminating the virus from within the
cell without killing it. Infected cells are assumed to be killed
by the CTL response at a rate k2YZand be cured by the CTL
response at a rate k1YZ. Infected cells produce free virus at a
rate k3Y and free virus particles are removed at a rate d3V.
CTLs proliferation can be described by two terms g4 and
k4YZ,whereg4 representsantigen-independentproliferation
and k4YZ represents antigen-dependent proliferation. CTLs
decay at a rate d4Z. ALT is generated by the dead hepatocytes
at a rate k5 and decay at a rate d5. All the variables and pa-
rameters of the above are nonnegative.
2.2. Equilibriumstatesanalysis
There are three possible steady states: Hepatocytes are
not infected—the uninfected state, all the hepatocytes are
infected—wholly infected state, and the coexisting state—
the uninfected and the infected hepatocytes coexist. As these
states are too complex to analyze, we only discuss the linear
ability of the most concerned state—uninfected state.
As the equation of Z is a logistic model, it will make the
expressionoftheanalysisresultverycomplex.Togetamean-
ing result easy for comparing with the clinical conclusion, we
ignore the limitation of Zmax as we only discuss small distur-
bance to the initial state (the maximum number of speciﬁc
T-cells can be 106 times of its initial number [20]).
As ALT is just an indicator of hepatic injury and do not
inﬂuence other variables, it is not included in the analysis
progress for simplicity.
Then the equations of the system can be rewritten as
dX
dt
= F(N)X − d1X −b1XV +k1YZ,
dY
dt
= F(N)Y +b1XV −d1Y −
 
k1 +k2
 
YZ,
dV
dt
= k3Y −d3V,
dZ
dt
= g4 +k4YZ− d4Z,
F(N) =
d1
N3 , N = X +Y.
(2)Changjiang Long et al. 3
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Figure 1: Acute hepatitis.
For the uninfected state (X = 1, Y = 0, V = 0, Z =
g4/d4), as it is an equilibrium state, it should satisfy dX/dt =
dY/dt = dV/dt = dZ/dt = 0, so get the coordinates  
1,0,0,g4/d4
 
. The correspondence Jacobian matrix is
⎡
⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎣
F (N) F (N)+
k1g4
d4
−b1 0
0
−
 
k1 +k2
 
g4
d4
b1 0
0 k3 −d3 0
0
k4g4
d4
0 −d4
⎤
⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎦
. (3)
The characteristic equation is
 
λ −F (N)
  
λ+d4
  
λ
2 +
 
d3 +Δ
 
λ+d3Δ − b1k3
 
= 0,
(4)
where
Δ =
 
k1 +k2
 g4
d4
,
∂N
∂X
=
∂(X +Y)
∂X
= 1;
∂N
∂Y
=
∂(X +Y)
∂Y
= 1,
∂F(N)
∂X
=
∂F(N)
∂N
∂N
∂X
= F (N),
∂F(N)
∂Y
=
∂F(N)
∂N
∂N
∂Y
= F (N),
F (N) =
∂F(N)
∂N
=
∂
 
d1/N3 
∂N
=
−3d1
N4 =− 3d1.
(5)
Since −F (N) = 3d1 > 0, d4 > 0, d3 > 0, Δ > 0, d3 +
Δ > 0, according to the Routh-Hurwitz criterion [21], if
d3Δ − b1k3 > 0, that is,
 
k1 +k2
 g4
d4
>b 1
k3
d3
,( 6 )4 Journal of Biomedicine and Biotechnology
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Figure 2: Fulminant hepatitis.
there will be linear stability with respect to perturbations in  
1,0,0,g4/d4
 
. The left-hand side of the equation represents
the ability of the immune system, k1 represents the nonlytic
ability of CTLs and k2 represents the lytic ability of CTLs.
Also, g4/d4 is the initial value of CTLs. The right-hand side
of the equation represents the ability of HBV, b1 represents
the infective ability of HBV, k3 represents the multiplication
ability of HBV, and d3 represents the death rate of HBV. If
the left part is bigger than the right part, it means that the
immune system is strong enough to eliminate the infection
otherwiseHBVcaninvadethebodyandexistforalongtime.
2.3. Simulation
By combining the various results derived in the previous sec-
tion we can deduce an appropriate parameter set for the sim-
ulation of the model.
Theparameters(1timeunit=1day)aresetupasfollows:
d1 = 0.002 (average life of hepatocyte is about 500d [13]);
d3 = 0.58 (estimated average half-life of free virions is about
1.2d[22]);d4 = 0.2(themeanlifeofCTLis4–6d[20]);d5 =
0.25 (average half-life of ALT is between 0.5–5 [13]); Zmax =
0.001 there should be no more than 108 HBV-speciﬁc CTL
in the entire body and there are approximately 1011 infected
hepatocytes in the human liver [23], as we took N = 1, so
Zmax = 108/1011); ALT0 = 16 (The normal range for ALT is
between 0–40).
3. RESULTS
3.1. Acutehepatitis
HBV can cause acute hepatitis, resulting in short-term in-
ﬂammation of the liver before the immune system is able to
remove the virus from the body. In acutely infected patients
whosuccessfullycontrolthevirus,theimmuneresponsethat
the patients produce against the viral proteins is polyclonal,
multispeciﬁc; and the virus is eliminated from the blood and
liver entirely. If the maximum damage and the maximum
concentrationoffreevirusarelow,thediseasemaycomeand
go without any symptoms, otherwise severe clinical symp-
toms will be observed.
The parameters during the simulation of acute hepati-
tis are set up as follows: d1 = 0.002; b1 = 3E − 5; k1 =
1E6; k2 = 1E3; b3 = 0.1; k3 = 800; d3 = 0.58; g4 =
1E − 8; k4 = 16; d4 = 0.2; k5 = 2000; d5 = 0.25; X0 =
1; Y0 = 0; V0 = 10; Z0 = 5E − 8; ALT0 = 16. As the cel-
lular immune response is vigorous and (k1 + k2)(g4/d4) =
0.0500 >b 1(k3/d3) = 0.0414, so the immune system is
strong enough to eliminate all the infected cells and virus.
The number of virus is at its peak at the beginning and
then decrease. HBV can only infect a small number of cells.
The number of infected cells
 
4.53 × 10
−4 
peaked at 7
days after infection. As the number is so small that the level
of serum ALT and the number of total hepatocytes almostChangjiang Long et al. 5
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Figure 3: Acute–turn-chronic hepatitis.
stay steady when the infected cells are eliminated by the
CTLs, viral clearance occur rapidly and eﬃciently with lit-
tle evidence of liver disease. Simulation results are shown in
Figure 1.
When the (k1 + k2)(g4/d4) − b1 (k3/d3) < 0, the cellu-
lar immune response is not able to eliminate all the infected
hepatocytes, so the virus will be persistent. In this case, if the
immuneresponseisstrongandmanyinfectedcellsarekilled,
it will be chronic hepatitis B. If the immune response is very
weak, there will be no symptom. If the virus has a strong in-
fectious capability and the immune response is vigorous but
not enough to resolve the infection, it will be fulminant hep-
atitis.
3.2. Fulminanthepatitis
The parameters during the simulation of fulminant hepatitis
are set up as follows: d1 = 0.002; b1 = 0.01; k1 = 100; k2 =
900; b3 = 0.1; k3 = 1000; d3 = 0.58; g4 = 1E − 10; k4 =
20; d4 = 0.2; k5 = 2000; d5 = 0.25; X0 = 1; Y0 = 0; V0 =
1E −5; Z0 = 5E − 8; ALT0 = 16.
Themortalityoffulminanthepatitisisupto60% ∼ 90%.
Inthiscase,thevirusrapidlyreplicatesandinfectseveryhep-
atocyte in the liver. Most infected hepatocytes are destructed
by the CTLs, resulting in severe liver dysfunction. Simulation
results of fulminant hepatitis are shown in Figure 2.
The initiation value of V0 is set as 10
−5 
106/1011 
,a sw e
assume transfusing 100mL of blood from an inactive car-
rier whose serum HBV DNA level was about 104 copies/mL
would deliver 1 × 106 
100 × 104 
particles of HBV into the
body.
As shown in Figure 2, hepatitis would outbreak sharply 7
days after the virus entered the body of a host. As the virus
has a strong infectious capability
 
b1 = 0.01
 
and replicates
rapidly
 
k3 = 1000
 
, 90% of the hepatocytes in the liver will
get infected within two days. The total number of HBV par-
ticles peaked at 794 × 1011 (equals serum HBV DNA level
= 2.6 × 1010 copies/mL). As the cellular immune response is
rapidly elicited
 
k4 = 20
 
, CTLs soon arrive the maximum
value. The cytopathic eﬀect of CTLs is more powerful than
its noncytopathic eﬀect
 
(k2 = 900) > (k1 = 100)
 
.M o s t
infected cells are killed by CTL directly and this would lead
to serious liver necrosis, and the level of ALT starts to rise
sharply, it peaks at 1223 at 7 day.
3.3. Acute–turn-chronichepatitis
The parameters during the simulation of acute–turn-chronic
hepatitis are set up as follows: d1 = 0.002; b1 = 0.005; k1 =
6000; k2 = 1000; b3 = 0.1; k3 = 600; d3 = 0.58; g4 =
1E − 10; k4 = 16; d4 = 0.2; k5 = 2000; d5 = 0.25; X0 =
1; Y0 = 0; V0 = 1E −7; Z0 = 5E −8; ALT0 = 16.6 Journal of Biomedicine and Biotechnology
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Figure 4: Chronic hepatitis.
HBV infection can become a chronic infection when the
immune system cannot ﬁght oﬀ the virus within six months
after infection. It will establish a chronic, lifelong infection
in the liver, and will have an enormously increased risk of
developing liver cancer. It is well known that the T cell re-
sponse is much less vigorous in chronically infected patients
than it is during acute infection. Simulation results of acute–
turn-chronic hepatitis are shown in Figure 3.
The initiation value of V0 is set as 10
−7 
104/1011 
,a s
we assume transfusing 1mL of blood from an inactive car-
rier whose serum HBV DNA level was about 104 copies/mL
would deliver 1 ×104 = 104 particles of HBV into the body.
The incubation period of hepatitis B caused by the virus
or blood transfusions is about 14 to 180 days. As shown in
Figure 3, hepatitis would outbreak 16 days after the virus en-
tered the body of a host. Eighty percent of the hepatocytes
in the liver would get infected within 16 days, total num-
ber of HBV peaked at 371 (equals serum HBV DNA level
= 1.2 × 1010 copies/mL). As the cytopathic eﬀect of CTLs
is so powerful
 
k2 = 1000
 
, many infected cells were killed
by CTLs, and the level of ALT peaked to 569 at 19 day.
3.4. Chronichepatitiswithoutacutephase
The parameters during the simulation of chronic hepatitis
without acute phase are set up as follows: d1 = 0.002; b1 =
0.2; k1 = 100; k2 = 40; b3 = 0.1; k3 = 0.8; d3 = 0.58; g4 =
1E−10;k4 = 30;d4 = 0.2;k5 = 2000;d5 = 0.25;g6 = 1E−10;
X0 = 1; Y0 = 0; V0 = 1E −8; Z0 = 5E −8; ALT0 = 16.
Many chronically infected people show little or no clin-
ical signs. The HBV-speciﬁc immune response is too weak
to eliminate HBV from all infected hepatocytes, but it is
strong enough to continuously destroy HBV-infected hep-
atocytes, maybe resulting in progressive tissue damage and
even cancer. Simulation results of chronic hepatitis without
acute phase are shown in Figure 4.
The incubation of the Hepatitis B is about 42 to180
days, average 180 days. The initiation value of V0 is set as
10
−8 
103/1011 
, as we assume that a hypodermic needle car-
ryingHBV-contaminatedbloodwhichcirculatesthroughthe
body will spread 103 virions. As shown in Figure 4,h e p a t i -
tis would outbreak 51 days after the virus entered the body.
Maximally 35% of the hepatocytes in the liver would get in-
fected, total number of HBV peaked at 0.56 (equals serum
HBV DNA level = 1.8 × 107 copies/mL). The level of ALT
reaches its peak value (104) at 117 day. The system will arrive
its steady state at 175 day, 15% of the hepatocytes in the liver
are infected cells, and total number of HBV is 0.24 (equals
serum HBV DNA level = 8 × 106 copies/mL) and the ALT
l e v e li s4 8 .
3.5. Recurringhepatitis
The parameters during the simulation of recurring hepatitis
are set up as follows: d1 = 0.002; b1 = 0.0002; k1 = 1000;Changjiang Long et al. 7
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Figure 5: Recurring hepatitis.
k2 = 2500; b3 = 0.1; k3 = 400; d3 = 0.58; g4 = 1E − 10;
k4 = 2.1; d4 = 0.2; k5 = 2000; d5 = 0.25; X0 = 1; Y0 = 0;
V0 = 1E −6; Z0 = 5E −8; ALT0 = 16.
When the viral concentration is at its lowest, the patient
may be diagnosed as complete recovery; but the virus never
completely disappears and an apparent reinfection will soon
appear. This recurrence will last for years. The simulation re-
sults of recurring hepatitis are shown in Figure 5.
3.6. Asymptomaticchronichepatitis
The parameters during the simulation of asymptomatic
chronic hepatitis are set up as follows: d1 = 0.002; b1 =
0.0001; k1 = 1; k2 = 4; b3 = 0.1; k3 = 100; d3 = 0.58; g4 =
1E − 10; k4 = 10; d4 = 0.2; k5 = 2000; d5 = 0.25; X0 =
1; Y0 = 0; V0 = 1E −7; Z0 = 5E − 8; ALT0 = 16.
Vertical transmission of HBV results in milder hepati-
tis in patients with no symptoms. The virus establishes it-
self in this immunologically immature population and is tol-
erated so that there will be no adequate immune response.
Neonatal tolerance is probably responsible for both the lack
of an antiviral immune response and the viral persistence af-
ter mother–infant transmission. This is the most common
antecedent of persistent HBV infection worldwide. The sim-
ulation results of asymptomatic chronic hepatitis are shown
in Figure 6.
4. DISCUSSION
The diversity of clinical syndromes and disease manifesta-
tions associatedwith HBV infection strongly suggests that
the clinical outcome of this infection is determined by
host-virus interactions, especially the quality and vigor of
the antiviral immune response produced by the infected
host. Most perinatal HBV infections become persistent,
presumably due to a suboptimalcellular immune response
that destroys some of the infected hepatocytes and does
not purge the virus from the remaining infected hepa-
tocytes. It thereby permits the persisting virus to trigger
a chronic indolent necroinﬂammatory liver disease that
sets the stage for development of HCC. In contrast, most
of the adult onset HBV infections resolve, presumably
due to the polyclonal, multispeciﬁc cellular immune re-
sponse that the patients produce against the viral proteins
[24].
Thequalitativeanalysisandsimulationresultssuggestthe
following pattern.
If the cellular immune response is vigorous and satis-
ﬁed
 
k1 + k2
 
g4/d4 >b 1k3/d3, the immune system is strong
enough to eliminate the infection. Otherwise, chronic hep-
atitis appears.
If the virus with strong infectious capability (b1 is large)
replicates rapidly (k3 is large), most hepatocytes in the liver8 Journal of Biomedicine and Biotechnology
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Figure 6: Asymptomatic hepatitis.
get infected, resulting in massive liver necrosis due to the
strong CTL response. The outcome will be fulminant hep-
atitis.
If the virus with weak infectious capability replicates
slowly,theCTLresponsetoHBVisrapid(k4 islarge)andvig-
orous(k1 +k2 islarge)enoughtoeliminatethevirusfromthe
blood and liver entirely. The outcome will be acute hepatitis.
If the maximum damage and the maximum concentration
of free virus are low, the disease may come and go unnoticed,
otherwise severe clinical symptoms will be observed.
If the immune system defends against HBV with a weak
killing ability (k1 + k2 is small) and weak CTL level (k4 is
small), the infected cells cannot be cleared out entirely. The
outcome will be chronic hepatitis with little or no clinical
signs.
This model is able to account for the diﬀerent outcomes
of HBV infection. However, this model can be further im-
proved to explain why many patients with acute hepati-
tis, whose hepatocytes are almost all infected, can recover,
and why many patients with chronic hepatitis B can get
rid of HBV when getting older. For the future studies, the
model will be applied to ﬁt clinical data for the evaluation
of immune states and virus characteristic, thus providing
information about the potency of antiviral therapies and
guiding the development of optimal drug dosages and reg-
imens.
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